ObHws. 'l&s dose-response study was designed to test two low dose rogimms of areklnase administered uver a prolunged time pedod in patieuts with chroak refractory aagloa pectorls witb mpect to e&cts 00 clinkal symptoms aad objective variabks ufmyocard&l iscbeiuii lladgmd Patknts wltb severe and chramk refractory aaglue pectork in end-stage corowy artery disease represent an increasing cliokal ptwbkm. Favarable tbcrapwtk e&cts oa myaeardlal kchemia have been reported for bng-tenn si~-8lkation of low dose orokiwse.
Metboth. Ninety-cl@ patients with cbrunk refwtury tmd end-stagecorouarytierydiseasewmrandomlyass@cdtotwo treatment groupsz gtwop A (49 patients) receiwd Stl,tl@ll IU aad gruup B (49 patients) seb,@tlO IU uf umklnase as aa iatravem bolusiqieetioatbreetilsesawedrmeraporiodot12~ Vtuiables evalaPted were number of weekly angloal CveitncS, data from ergometric exercise testing wlth simultatwus ekctrucaniii Therapeutic options for the management of angina pectoris in patients with coronary artery disease have increased and improved impressively over the past 25 years. Next to ?be three mainstays of medical therapy (nitrates, beta-adrenergk blocking agents and calcium antagonists). invasive procedures such as coronary artery bypass graft surgery and percutaneous transluminal coronary balloon angioplasty have been established as effective means of reducing myocardial &hernia and hence angina1 symptoms. Still, clinicians can identify patients with severe symptomatic coronary artery disease who are refractory to conventional medical as well as to invasive therapeutic approaches. Because sun+1 of patients with graphic registration, .:emiquantitative cvaluatian of Tc-99m 2-metboxy isobutyi isoaitik (MIBI) scans sod rbe&jc vsrhbks. Red&. After It we&s of treatment, aaginal symptums (events/ week) were reduced signilkantly in gruup B by 70% compared wltb 24% in group A (p < @.ftOl). Fibrioogen d===fby=iBgrollP Aradby3J%io~pB(p<Q.801).Plrs~visrosityoadIpd blood cell slggmgatioo were redoccd by 6.4% (p < e.aw and 19.9% (p < O.@tJl,, respectively, in gruup B. O&-tiw wiables of lgtocPrdblisebeDdrWUViolpwcdsij@BUatlyin@UEpBOIdy.Nn cltmulatlonofLwoDplrkcltemkeventswsobsavedktgcnopR m. Long+rm iatermitteat oroldnase therapy in aa applleddaseof3xXKt,~lU/weekreprwotsaaefective aati-iscbcmk and antiaaginal appruad8 for patknts ti t+ac-toryaegiaapectorisandend-stagecumaary~dlsease.Apart from rhwlogk impmvemen~ autlthrumbotk prupcrtks and plaque regrrssioa are likely anti-lscbemk mechanisms.
(J Am Cdl Gvdiol199&27:575-84) coronary artery disease is increasing as a result of improved secondary prevention, ar. increase in the prevalence of patients with refractory angina pectoris is to be expected.
For patients with refractory angina pectoris, long-term intermittent urokinase therapy as a combined rheologk and thrombolytic approach to the improvement of myocardial perfusion was developed (1.2). The first observational studies in patients with refractory angina pectoris (3.4). which evaluated the effect of 3 X 5tWOO IU urokinasetieek over a period of 12 weeks, demonstrated a significant amelioration of anginal symptoms and objective signs of myocardial ischemia accompanied by a significant reduction in fibrinogen levels.
To further investigate the validity of these observations, a dose-response study was designed that compared the intravenous administration of 3 X 50,000 1U of urokinase with a dosage of 3 x XWOO IU urokinaAweek over a period of 12 weeks. The objective was to demonstrate whether there is a dose-dependent influence of long-term intermittent urokinase therapy in patients with retioty angina pectork regarding 1) clinical symptoms of 111. -. fial isehemia, 2) objective vatiables of myocardial is&en.., and 3) safety of this form of therapy.
Methods
Study design. The study was designed as a single-blind trial in which patients had no knowledge of the dosage and were randomly assigned to one of two treatment groups. In both groups, urokinase (Urokinase Medac) was administered intravenously as a bolus injection three times a week over a period of 12 weeks (36 injections). Patients in group A received .5O.GI Ill/injection, and those in group B received 5OO.ooO IU/ injection.
During the outpatient treatment period, laboratory variables as well as diaries for evaluation of angina1 symptoms were checked every 2 weeks; conventional medication included low dose aspirin (!OO mgiday) in all patients and was continued as prescribed at the beginning of the trial. Ergometric exercise testing and myocardial stress scintigraphy were performed before and after the treatment period.
To guarantee maximal safety for patients undergoing a long-term therapy with a thrombolytic agent, and in accordance with the standards set for this study by the ethics committee of the medical faculty of the Heinrich-Hcine University, injections of urokinase and primary evaluation of angina diaries and laboratory variables were carried out in a single-blinded manner. Final evaluation as presented in this report was double-blind for angina diaries; laboratory variables; and two independent studies of exercise testing, including ST segment analysis and myocardial stress scintigraphy.
All patients were enrolled in the study with the approval of the prima:y care physician. and all patients gave written informed consent. The study was approved by the ethics committee of the Heinrich-Heine University.
Patients. The study included 98 patients with severe angina pectoris (Canadian Cardiovascular Society angina class III or IV IS]) de+ite the maximal antianginal therapy (beta-blockers nitrates and calcium antagonists) that did not produce relevant side effects. Patients with chronic intermittent episodes of chest pain at rest were also classified as eligible If they did not have newly developed rest pain within the preceding month or other forms of unstable angina pectoris (6). The option for an invasive revascularization procedure had been ruled out before entry into the study by an experienced team of cardiologists and cardiac surgeons after review of a coronary angiogram that had been assessed within 3 months before entry into the study. The major reason for exclusior! firm rivascularization procedures was unsuitable coronary anatomy for mechanical interventions, such as dilfuse coronary atherosclerosis which extended to the periphery of the epicardial conductance vessels. Further criteria for exclusion were repeated unsuccessful interventions in the culprit lesion for reduction of myocardial ischemia, lack of graft material and a high peri-interventional risk due to severe left ventricular dysfunctkm in some patients. Because the study was directed toward evaluation of the rheologic impact of long-term intermittent urok&se therapy, patients with fibrinogen levels >250 mg/dl W+ZR selected to increase the chance of detecting a relation behveen clinical benefit and improvement of blood rheohqic variables.
Throughout the trial. conventional antianginal medication as well as l(W) mg aspirin/day WPS continued in each patient. Patients were not included in the trial if they met one or more of the following criteria: myocardial infarction within the preceding 6 months, severe heart failure (New York Heart Association functional class IV), hemodynamically significant valvular heart disease, hypotension (systolic blood pressure < to0 mm Hg) or hypertension (systolic and diastolic blood pressures >I60 and ~90 mm Hg, respectively), clinical evidence of intermittent tachyarrhythmia. evidence of chronic inflammatory disease or other relevant organ dysfunctions or contraindications for anticoagulation.
Patients were excluded from final evaluation if they developed one of the following conditions during the course of treatment: subjective discomfort. gastrointestinal bleeding, rcduction of fibrinogen levels < I50 mg/dl, myocardial infarction or death. Patients with an increase of angina1 events by ~56% during two successive weeks were excluded from further treatment for possible adverse reactions. These patients were again admitted for in-hospital monitoring for unstable angina pectoris and treated accordingly. Screening procedures for bleeding complications (serial blood count. stool guaic test, endoscopy) were performed according to clinical judgment with a high index of suspicion. Patients with evidence of bleeding complications were excluded from further treatment. Under these preconditions, the final evaluation included 43 patients in group A acd 46 patients in group B.
Evaluation of spontaneous anginaI symptoms. Patients recorded the number of angina1 episodes as well as the intake of the number of fast-release nitrate capsules daily in a diary. As for the known placebo effect of -40% in antiangina] studies (7.Q positive responders were classified as patients who had relief of symptoms during the final 2 weeks of the trial by ~66% compared with the initial number of weekly anginat episodes.
Ergo&& exe&e testing and ST segment dysis. Two independent exercise texts (bicycle ergometry) that included electrocardiographic registration (leads I, II. Ill, V, V.,, V,), were performed before and after 12 weeks of treatment.
Patients who received digitalis, demonstrated left bundle branch block or atrial fibrillation or who had a cardiac pacemaker were excluded from evaluation of ST segment changes. End points for exercise testing were chest pain. exhaustion or ST segment depression ~0.3 mV. &mciw s&y I. Exercise was performed in the sitting position and started with 25 W, work load was increased every I20 s by 25 W. Patients exercised until they reached one of the end points before and after treatment. Variables evaluated in all patients were I) end point at termination of exercise 2) exercise capacity as expressed by cumulative work performed (J), 3) maximal heart rate (beats/min) and nte-prc~re product(MaximaItlealtntexMaximat~hbaIprer-sure x 0.01). blood added to 1 ml of sodium citrcte (Multifibren. Behringwerke). Fibrinogen levels were shown to be 227 ? 50 mg/dl (mean -C SD) (n = 16) in healthy subjects and to 295 t 69 mgldl (n = 44) in patients with coronary artery disease and stable angina pectoris (14). Plasma viscosity was measured in venous blood anticoagulated with EDTA at 37°C in a capillary tube viscosimetel (KSPV 4. Rheomed). In healthy subjects a mean value of 1.24 -C 0.07 mPa X s (n = -34) was found. but in patients with coronary artery disease and nonrefractov an&ma pectoris. a mean value of 1.33 ? 0.08 mPa X s (n = 78) (14) was reported.
Red blood cell aggregation was analyzed at instananeous hematocrit with the aggregometer MA-I (Aggregometer, Myrenne GmbH), which uses the light transmission meihod according to Schmid-Schoenbein et al. (15) at zero shear rate. The mean value was fol;nd to be 9.6 t 3.2 U in healthy subjects (n = 28) and 13.1 -C 3.1 U (n = 42) in patients with coronary artery disease and nonrefractory angina pectoris (14).
Statistics.
The data were analyzed with the statistical software SPSS 6.0. Baseline characteristics of the study groups were tested for significant differences with the Student r test for unpaired observations and the chi-square test. The time course of dependent variables was tested for intergroup differences with a two-way repeated-measures analysis of variance model. Where needed, correlation coefficients were generated with the Pearson bivariate correlation test.
Results

Patients.
Of the 98 patients admitted to the study 70%, had undergone coronary artery bypass (Table 1) . Almost all patients suffered from coronary triple disease; about 50% of the bypass vessels implanted were occluded. In addition to severe coronary insufficiency, relatively large amounts of viable myocardium could be assumed as reflected by an only moderately impaired left ventricular function at rest. Patients demonstrated pathologic elevations of rheologic blood properties, as fibrinogen levels and dependent rheologic parameters were elevated not only in respect to normal controls but also in comparison to patients with coronary artery disease and nonrefractory angina pcctoris (14). Twothirds of the patients had angina class IV; only 60% tolerated antianginal triple combination therapy. Both groups were comparable in respect to baseline parameters except for a higher incidence of myocardial infarction in the history of patients in group B.
Laboretoq variables. Only group B demonstrated a significant decrease of fibrinogen levels with reductions by an average of 33% at the end of the study compared with 3% in group A (Table 2) ; these were accompanied by reductions of plasma viscosity (-05% in group A; -6.4% in group B) and red blood cell aggregation (-5.1% in group A; -19.% in group B). As expected, there was a highly positive correlation between fibrinogen and plasma viscosity (r = 0.78, p < 0.001) and red blood cell aggregation (r = 0.60. p < 0.001) over the whole group. Aogioal symptoms. Reductions of angina1 symptoms (events/week) were associated with changes of rheologic variables in their time course (Fig. 2) . with a reduction of 25% in group A and 70% in group B ( (Table 4) . exercise capacity increased markedly by 60% in group B. In group B, a significant reduction in patients who "stopped for angina pectoris" which represented a shift of end points from "stopped for angina pectoris" to "stopped for exhaustion," could be demonstrated. Averaged ST segment depression decreased signiticantly only in group B in addition to an increase in "time to angina pectoris" and "time to negative ST segment depression >O.l mV."
Premise sr~dy II. Roth groups showed no signiticant differences of maximal heart rate and rate-pressure product (Table  4 ) before and after treatment indicating a comparable level of myocardial stress. Results reflected those from exercise study I insofar as significantly fewer patients stopped exercise with angina pectoris in group B. Average ST segment depression at the end of exercise was significantly reduced in group B after the treatment period. as was time to ST segment depression of 0.1 mV.
Myocadal seimtigmpby. Myocardial stress as expressed by the results from exercise study II (Table 4) was comparable before and after treatment in both groups. After treatment the scintigrapbic stress index as a variable of myocardial pemsion was significantly reduced toward zero in group B (from 269 ? 95 to 231 2 84. p < 0.014) as compared to the timely change in group A (from 249 2 76 to 258 ? 91) (Fig. 3) .
!Me e&ts. In five patients in group A and two patients in group B, treatment had to be stopped for an increase ofclinical symptoms by ~56%. indicating unstable angina pectoris or myocardial infarction ( treatment, which could be attributed to duodenal ulceration. The cardinal symptom was tarry stool, and hcmoglocin was reduced to a minimum of I I .2 g/d1 (IS.6 g/d1 before treatment); hemostatic variables were measured in the normal range (fibrinogen 240 mg/dl. activalzd partial thromboplastin time 30 s). Even though no clear evidence for a prior history of gastroduodenal ulcers could be establislvd. it seems probable that treatment with aspirin may have had a triggering effect on latent ulcer disease in this patient. In 24 patients in group A and in 27 patients in group B. blood counts were assessed at the ber.,:xing of the study and within the last 4 weeks of treatment. No significant differences could be documented hetween time points or between groups in respect to red blood cell count, hematocrit. platelets or white blood cells.
Discussion
Anti-ischemic effectiveness of long-tenn intermittent urokinase therapy.
This study provides strong evidence for a dosedependent favorable effect of long-tcrrn intermittent urokinase therapy on myocardial ischemia and angina pectoris in patients with refractory angina pectoris in end-stage coronary artery disease. A therapeutic regimen of 3 X SOO,O@O IU urokinasel week over d period of 12 weeks produced significant reductions of clinical symptoms after 2 to 4 weeks accompanied by significant improvements of variables of myocardial &hernia at the end of the study. Even though the low dose used in group A (3 X 50.000 IU urokinasefieek over a period of 12 weeks) Icd to a significant decrease of angina1 attacks, this may have to be attributed lo a placebo effect, as reductions averaged 25%, which ranges within the limits of known placebo effects (7,8). The favorable changes of objective variables of stress-induced myocardial &hernia demonstrated in group B were not accompanied by significant decreases of determinants of myl,cardial oxygen demand such as heart rate and ratepressure product. Therefore, the reduction of myocardial ischemia has to be attributed to an increase of oxygen supply and not to a peripheral training effect (16).
Rhdogic mechanisms of anti-M ehctiieness. Because the favorable therapeutic effects in group B were accompanied by significant decreases of fibrinogen, it can be assumed that therapeutic effectiveness is in part mediated by the improvement of rheologic blood properties and subsequent increases in blood fluidity. In nonobstructed coronary arteries, the flow-limiting resistance caused by blood viscosity, which is mainly determined by plasma viscosity, red blood cell aggregation, red blood cell deformability and hematocrit, can be Antitbrombotii mecbaoisms of anti-iscbemk effdveness.
Apart from the acute coronary syndromes. plaque fissures or thrombi have been demonstrated in the coronary arteries of 22% of patients with atheroma-related disease who died of noncardiac causes (23). Therefore, they may be of flow-limiting relevance in the epicardial conductance vessels (24) Prodlrombogenic factors may also be of particula: relevance in venous graft material, which i, inferior to autologous mammary-coronary anastomosis because of a higher rate of graft closure (31$2). Even though coronary ilow reserve normalizes after bypass grafting (33.34), endotheliumdependent flow-mediated relaxation is impaired in venous as compared to arterial grafts (35). These functional differences, and the fact that the arterialization of venous grafts leads to profound fluid dynamic changes that increase the wall stress of the vessel (36). lead to early structural alterations (37) that further promote thrombosis in venous bypass vessels.
These aspects of thrombogenic and therefore dynamic impairment of blood flow stress the relevance of antithrombotic and thrombolytic eRcacy of long-term intermittent urokinase therapy as a major factor for the improvement of myocardial perfusion. The thrombolytic potential of different therapeutic regimens at low dose has been demon&rated (338,39). Furthermore two recent Uudies on the ad-ischemic efficacy of low molecular weight heparin (40,41) contributed to the concept of antithrombotic therapy as an anti-ischemic approach in stable angina ~0ri.s. Apart from the induction of collateral angiogenesis and functional improvement of cdl&-crab (41-44). antithrombotic efficacy of low molecular weight heparin (29.40) is likely to bc of relevance.
Asms of plaque regression for anti-ischemic electiveness. It has been demonstrated that fibrinogen and fibrin are major constituents of atherosclerotic plaques (45-47) and high levels of fibrinogen are positively correlated with the extent of atheroma in the coronary and carotid arteries (48.49). This is regarded as a result of repetitive plaque rupture with formation of coronary thrombus, which, because of incomplete endogenous lysis, becomes incorporated into the plaque with subsequent rapid, nonlinear morphologic plaque progression (24). In addition, high fibrinogen levels in plasma lead to direct permeation of fibrinogen with an increased content of fibrin in the plaque (45). It is therefore probable that long-term thrombolytic therapy may lead to actual morphologic plaque regression, which is of particular relevance for blood flow in critically stenosed arteries.
Potential pfothrombotii side effects of long-term iatermittent wokinase therapy. Investigations on thrombolysis in unstable angina have demonstrated a cumulation of acute coronary ischemic events (50-52) in the treatment groups. which have been attributed to a variety of probable mechanisms such as increased thrombin generation (53-57), activation of platelets (58-60) and exposure of thrombogenic plaques (61) . In contrast, it seems that mild thrombolytic therapy may have a favorable impact regarding these end points. Acute coronary events were reduced in group B, which received 3 X 500,CKlO IU urokinase, in comparison to the group that received the lower dosage (two patients vs. five patients). The low rate of acute ischemic events in the group that received 3 x 500,000 IU urokinase may be attributed to the daily oral administration of aspirin in all patients and the low dosage of urokinase used. It is at this point of interest to note that in patients with unstable angina, regimens with low dosages and prolonged infusiin of thrombolytic agents (62) may be superior to high dosages given over a short period.
Limitations ol the study. A single-blinded study design was chosen for safety reasons. The absence of a placebo group is noteworthy because the inclusion of a true placebo group might have demonstrated even more signilicant effects for an application of 3 X 500.000 IU urokinase than did the comparison with the group that received 50,000 IU urokinase/ injection. In contrast, placebo effects on clinical efficacy are not completely ruled out by the study design chosen.
The increase in exercise time to ST segment depression of 0.1 mV in group B may seem small in relation to the marked reduction of spontaneous angina1 symptoms. Exercise testing was undertaken to assess maximal exercise capacity. but the record of spontaneous artginal symptoms does not necessarily reflect functional class. According to the data presented, functional exercise capacity increased by -60% in group B. In addition, results from exercise study I indicate that silent ischemia may have been a eottsiderabIe factor in group B. as 35 patients reached negative ST segment &pres&n of 0. I mV on both occasions while the end point of augiaa peetoris was reduced from 32 to 14 after treatment. Repeated Holter recordings could hdve yielded valuable results on the interaction betw-en this form ot therapy and angina threshold, and hence coronary vasomotion and therapeutic effectiveness in respect to silent ischemia.
ConclusIor~s. The anti-ixhemic and antianginal effectiveness of long-term intermittent urokinase therapy in addition to maximal conventional medical therapy implies that there do exist additional determinants of myocardial ischemia apart from the established therapeutic approaches that mainly influence oxygen supply at the level of the epicardial coronary arteries or modify myocardial oxygen demand (63) (64) (65) (66) . This circumstance stresses the importance of factors that modulate coronary microcirculation and therefore myocardial perfusion, as has been emphasized previously for other diseases of the heart (6768). In addition, aspects of thrombogenesis in these highly symptomatic though clinically rather stable patients seem to be of particular relevance, as demonstrated by the efficacy of antithrombotic intervention. As these factors seem to be critical for myocardial perfusion under the given circumstances. refractory angina pectoris in end-stage coronary artery disease may be regarded as a distinct coronary syndrome (69 
